Boston Pharmaceuticals Hires New CMO

Peter Ho, MD, PhD will be taking the helm at Boston Pharmaceuticals, accelerating the advancement of BOS172738, the novel RET inhibitor the company acquired in August 2017 from Daiichi Sankyo, as well as a diversified portfolio of candidates. Dr. Ho was appointed Chief Medical Officer because of his impressive drug development career, having been directly responsible for first-in-human dosing of 17 anti-cancer agents and overseeing the development of over 50 hematology and oncology compounds.

Dr. Ho joins Boston Pharmaceuticals from Epizyme where he was also CMO. Prior to this, he co-founded and served as President of BeiGene Ltd. after serving in a number of leadership roles at pharmaceutical giants including Johnson & Johnson, GlaxoSmithKline, and Novartis.

Finn Partners Gains New Partner

As part of its expansion in the Midwest, Finn Partners has added Christopher Bona as a Partner in the agency’s Health Practice. Bona brings more than 20 years of Chicago-area pharma experience to the digital health communications group, having led world-class accounts with pharma, medical device, and health/tech clients.

“Our clients and our team will benefit from Chris’ extensive industry experience with trusted health brands across both medical device and biopharmaceutical products. He brings deep knowledge across the sector, plus, he understands client brand-building pressures and priorities,” Kristie Kuhl, JD, Senior Partner, Finn Partners, said in a statement. Bona was previously the lead of global marketing communications at GE Healthcare’s Detection & Guidance Solutions and has held executive positions at Baxter International and Abbott.

Advicenne

Linda Law, MD joined the biopharma company as U.S. Vice President, Clinical Development and Medical Affairs. Dr. Law has more than 20 years experience in the international pharmaceutical arena and will oversee Advicenne’s clinical development and medical affairs efforts in North America.

Crinetics Pharmaceuticals

Marc Wilson has joined the rare disease company focused on developing therapies for endocrine disorders and cancers as Chief Financial Officer. Wilson joins Crinetics from Cidara Therapeutics where he served as Vice President of Finance and Accounting and Chief Accounting Officer. He was also an asset to the financial departments of Trius Therapeutics and Neurocrine Biosciences.

DanDrit Biotech USA

DanDrit Biotech appointed Ambassador Mark Dybul, MD, as the Chairman of its Scientific Advisory Board. Dr. Dybul is the inaugural Global Health Fellow of the George W. Bush Institute and Managing Director of the Office of the U.N. Special Envoy for Malaria. He has also served as Deputy Chief Medical Officer of the President’s Emergency Plan for AIDS Relief since 2004.

Foamix Pharmaceuticals

The specialty dermatological pharmaceutical company appointed David Domzalski, Foamix’s CEO, to its Board of Directors. Domzalski first joined Foamix in 2014 as President of the U.S. subsidiary and became CEO in 2017. With more than 25 years experience, he has been instrumental in leading the company’s successful IPO and subsequent follow-on offerings.

GlaxoSmithKline

Filippo Lanzi, who originally joined GSK as part of a joint venture between the company’s Consumer Healthcare division and Novartis’ OTC business, is the company’s new Asia Pacific Regional Head. He will oversee operations in 23 countries as a member of GSK’s consumer healthcare strategic leadership team. Lanzi previously held leadership roles at Novartis, Johnson & Johnson, and Nestle.

Juno Therapeutics

Juno tapped ex-Genentech VP, IT for the Americas, Cindy Elkins, as Chief Information Officer. Prior to serving Genentech, where she was instrumental in pushing the company to become the first biotech to implement several key technology platforms on a large scale, Elkins was VP and General Manager at IT firm, Ariba.

Novartis

Novartis tapped Pfizer’s Global President of Oncology, Liz Barrett, as the new CEO of Novartis Oncology. Barrett has been with Pfizer since 2009, and served three years as President, overseeing the launch of blockbuster cancer therapy, Ibrance, and award-winning Besponsa. Before joining Pfizer, Barrett was a key contributor at Cephalon and Johnson & Johnson.

OncoResponse

OncoResponse expanded its scientific leadership with the addition of Anil Singhal, PhD, as Chief Scientific Officer and Kamal D. Puri, PhD, as Vice President, Research and Development. Dr. Singhal most recently led the global regulatory approvals of Empliciti in multiple myeloma and Zinbryta in multiple sclerosis for AbbVie. Dr. Puri’s 20 years experience in research and development in immunology, oncology, and neurobiology stems from his success in developing new molecular entities for Celgene’s pipeline.

Outcome Health

Vince Panozzo was promoted to EVP of Sales. He will set strategy for customer acquisition and will focus on customer experience for healthcare providers, life sciences customers, pharmaceutical manufacturers, and lifestyle brands. Prior to joining Outcome Health, Panozzo was SVP and Chief Revenue Officer at Strata Decision Technology.

Regentys

Regentys has named Dr. John F. Howes Vice President of Clinical and Regulatory Affairs, where he will be responsible for the overall planning and direction of clinical and regulatory activities. Dr. Howes has been consulting in the medical field since 2007 and was previously VP of New Drug Development at IVAX/TEVA.

Sobi

Sobi has appointed Holly May to bring the rare disease company’s medicines to the U.S. as its new Vice President of Sales and Marketing U.S. With more than 20 years of experience in biopharmaceutical marketing, she is considered the perfect candidate for launching new products and ensuring patient access. She most recently served as Head of U.S. Marketing for Fabry disease at Sanofi Genzyme.

Tarveda Therapeutics

Brian Roberts is now Chief Financial Officer of Tarveda, based on his 25-year record in delivering positive results and driving stakeholder value in the life sciences field. Prior to this, Roberts served as CFO and COO at Avedro, Inc.

WCG

Shannon Bledsoe is now Executive Director at WCG, where she will be responsible for leading overall organizational growth, strategic direction, and overseeing the quality of WCG’s programming. She brings more than 20 years experience from various leadership positions at global non-profits advocating for public health and reproductive rights.

Ads

You May Also Like

The Sunshine Act’s Impact on MSLs Interactions with KOLs

A recent survey conducted by the MSL Society and the Rutgers Institute for Pharmaceutical ...

Midday Crash? Take a “NASA Nap”

What’s every adult’s dream job? It could be one that allows naptime. Yes, naptime. ...